Mounjaro week 3: separating real effects from TikTok glow-ups
Quick answer
The creator is a perimenopausal woman in week three of tirzepatide (Mounjaro), reporting constipation requiring laxative intervention, 0.4 lb weekly weight loss, and subjective improvements in mood, energy, and anxiety she attributes to the medication. She is self-titrating her eating behavior in response to delayed gastric emptying and has not yet escalated beyond the initial 2.5 mg dose. Her mood and anxiety symptoms predate this video and she has not reported using any concurrent hormonal or psychiatric medications.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @itscharmbell actually say?
In her week three update, @itscharmbell reported constipation bad enough that she needed an over-the-counter laxative, a modest weight loss of "0.4 pounds," improved energy, better mood, and reduced anxiety. She also said she'd only now learned, three weeks in, that she needs to eat slowly to feel fullness cues. She credits Mounjaro specifically for lifting what she describes as perimenopause-related low moods and anxiety, going so far as to say "I would literally take it just for the menopause." That last claim is worth pausing on.
She also frames her first dose as a "loading dose," which is a specific pharmacological term. Whether she's using it accurately matters, so we'll get into that.
Does the science back this up?
Mostly, yes, with some important caveats. The constipation, the slow eating learning curve, the modest early weight loss, and the mood improvements all line up reasonably well with what clinical data shows. The perimenopause framing is more complicated.
Constipation is one of the most commonly reported side effects of GLP-1 receptor agonists. In the SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine), gastrointestinal side effects including constipation were reported in roughly 17-18% of tirzepatide participants at higher doses. Gastric emptying slows significantly on tirzepatide, which is the mechanism behind both satiety and the gut discomfort she's describing.
On mood: there is emerging, genuinely interesting research here. A 2023 observational study (Mansur et al., 2023, JAMA Network Open) found associations between GLP-1 receptor agonist use and reduced rates of depression and anxiety in people with obesity, though causality is not established. Weight loss itself improves mood through multiple pathways. Separating drug effect from weight effect is hard, and nobody should be starting tirzepatide as a mood treatment.
On perimenopause and weight: progesterone and estrogen shifts do complicate fat distribution and metabolism, so her instinct that hormonal changes are fighting her weight loss is not wrong (Davis et al., 2012, Climacteric).
What did they get wrong (or right)?
The "loading dose" framing is inaccurate. She got this one wrong. Tirzepatide starts at 2.5 mg weekly not because it is a loading dose, which in pharmacology means a higher initial dose to reach therapeutic levels faster, but for the opposite reason: to minimize gastrointestinal side effects while the body adjusts. The starting dose is actually the lowest dose in the titration schedule (Frías et al., 2021, New England Journal of Medicine).
What she got right is the eating-slowly lesson. GLP-1 and GIP receptor co-agonism with tirzepatide significantly delays gastric emptying. If you eat at your old pace, the food is physically not moving through fast enough. She learned this the hard way, which is exactly how most people learn it, but the physiological explanation is sound.
Her mood and energy reports are credible self-observations. She is not claiming Mounjaro treats menopause or depression. She is describing her personal experience. That is fair. The concern is that her framing, "I would literally take it just for the menopause," could lead followers to pursue a prescription under false pretenses. GLP-1 agonists are not approved for perimenopausal symptom management.
What should you actually know?
If you are considering tirzepatide and you are perimenopausal, here is what the evidence actually supports: tirzepatide can produce meaningful weight loss, and weight loss during perimenopause can reduce some hormonal burden and associated mood symptoms. It does not treat the underlying hormonal fluctuations. Hot flashes, night sweats, and vaginal atrophy are not going to respond to a GLP-1 agonist.
Constipation on tirzepatide is common, not a sign something is wrong, but worth managing proactively. Fiber intake, hydration, and physical activity are first-line approaches. Reaching for a laxative at week three is not ideal as a routine strategy, though it is not dangerous.
- The 0.4 lb loss in week three is not failure. Early weight loss on GLP-1 therapies is often front-loaded or inconsistent while the body adjusts to gastric emptying changes and caloric reduction.
- If mood improvement is a significant motivator for you, discuss that with your prescriber. They need the full picture to monitor you appropriately.
- Do not interpret another person's TikTok experience as a clinical predictor of your own response.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Tirzepatide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Mounjaro week 3: separating real effects from TikTok glow-ups, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Compounded Tirzepatide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Claim path
Keep researching this tirzepatide video claims cluster
Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.
Claim verdict
The useful answer behind this video
Claim being checked
The creator is a perimenopausal woman in week three of tirzepatide (Mounjaro), reporting constipation requiring laxative intervention, 0.
FormBlends verdict
The creator is a perimenopausal woman in week three of tirzepatide (Mounjaro), reporting constipation requiring laxative intervention, 0.4 lb weekly weight loss, and subjective improvements in mood, energy, and anxiety she attributes to the medication. She is self-titrating her eating behavior in response to delayed gastric emptying and has not yet escalated beyond the initial 2.5 mg dose. Her mood and anxiety symptoms predate this video and she has not reported using any concurrent hormonal or psychiatric medications.
Patient-safe next step
Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator is a perimenopausal woman in week three of tirzepatide (Mounjaro), reporting constipation requiring laxative intervention, 0.4 lb weekly weight loss, and subjective improvements in mood, energy, and anxiety she attributes to the medication. She is self-titrating her eating behavior in response to delayed gastric emptying and has not yet escalated beyond the initial 2.5 mg dose. Her mood and anxiety symptoms predate this video and she has not reported using any concurrent hormonal or psychiatric medications.
- Tirzepatide's 2.5 mg starting dose is a low introductory dose to reduce GI side effects, not a loading dose. Loading doses are higher-than-maintenance doses, the opposite of how tirzepatide titration works.
- Constipation affects roughly 17% of tirzepatide users per the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM). Managing it with fiber and hydration before reaching for laxatives is the preferred clinical approach.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.
Review Compounded TirzepatideWhat You'll Learn
- Tirzepatide's 2.5 mg starting dose is a low introductory dose to reduce GI side effects, not a loading dose. Loading doses are higher-than-maintenance doses, the opposite of how tirzepatide titration works.
- Constipation affects roughly 17% of tirzepatide users per the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM). Managing it with fiber and hydration before reaching for laxatives is the preferred clinical approach.
- A 2023 JAMA Network Open observational study found associations between GLP-1 agonist use and reduced depression and anxiety, but causality is unproven and these drugs are not approved mood treatments.
- 0.4 lb of weekly weight loss in week three is within normal range for the low starting dose. Tirzepatide produces the most significant losses as doses escalate and body composition shifts over months, not weeks.
- Perimenopause does affect fat distribution and metabolism through estrogen and progesterone changes, but tirzepatide does not address hormonal fluctuations directly and is not a substitute for evidence-based perimenopausal care.
- Eating pace matters significantly on tirzepatide. Delayed gastric emptying means food clears the stomach much more slowly, and eating at a pre-medication pace is a leading cause of nausea, bloating, and discomfort in early weeks.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Charm Bell · TikTok creator
18.1K views on this video
Week 3 has taught me to listen to my body’s response to food by eating slower. The body is digestibg at a much slower rate. Shout out to #mounjaro for the energy levels, the great sleeps and bring my moods back to joy and gratitude #mounjaro #weightloss #perimenopause #healthyliving #glp1forweightloss
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Charm Bell, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.